Atopic dermatitis (AD) is a T helper 2-mediated chronic infammatory skin disease that afects children and adults. Patients with AD are prone to recurrent infections of the skin and other organs, which can severely worsen the disease course. This review summarises the current evidence on the aetiology, pathogenesis, treatment and prevention of infections in patients with AD. PubMed was searched for English-language research articles, systematic reviews, meta-analyses and guidelines published until February 2023 using the key term “atopic dermatitis” and terms relevant to infections. Patients with AD have an increased risk of bacterial, viral and fungal infections of the skin, mainly due to impaired barrier function, altered immune response and frequent scratching. The most common pathogens are Staphylococcus aureus and herpes simplex virus, which can cause impetigo, folliculitis, abscesses, eczema herpeticum and other complications. They also appear to increase susceptibility to systemic infections, including respiratory and urinary tract infections and sepsis. Certain systemic treatments for AD, such as mycophenolate mofetil and Janus kinase inhibitors, increase the risk of viral infections. Prevention and treatment of recurrent infections in patients with AD require a multifaceted approach that includes topical and systemic antimicrobials, skin care and efective control of AD symptoms (to break the itch–scratch cycle). Preventing and limiting the development of infections are important considerations in choosing an AD treatment.

Infections in Patients with Atopic Dermatitis and the Infuence of Treatment

· Giampiero Girolomoni;
2024-01-01

Abstract

Atopic dermatitis (AD) is a T helper 2-mediated chronic infammatory skin disease that afects children and adults. Patients with AD are prone to recurrent infections of the skin and other organs, which can severely worsen the disease course. This review summarises the current evidence on the aetiology, pathogenesis, treatment and prevention of infections in patients with AD. PubMed was searched for English-language research articles, systematic reviews, meta-analyses and guidelines published until February 2023 using the key term “atopic dermatitis” and terms relevant to infections. Patients with AD have an increased risk of bacterial, viral and fungal infections of the skin, mainly due to impaired barrier function, altered immune response and frequent scratching. The most common pathogens are Staphylococcus aureus and herpes simplex virus, which can cause impetigo, folliculitis, abscesses, eczema herpeticum and other complications. They also appear to increase susceptibility to systemic infections, including respiratory and urinary tract infections and sepsis. Certain systemic treatments for AD, such as mycophenolate mofetil and Janus kinase inhibitors, increase the risk of viral infections. Prevention and treatment of recurrent infections in patients with AD require a multifaceted approach that includes topical and systemic antimicrobials, skin care and efective control of AD symptoms (to break the itch–scratch cycle). Preventing and limiting the development of infections are important considerations in choosing an AD treatment.
2024
Patients with atopic dermatitis (AD) are prone to recurrent bacterial, fungal and viral skin infections that can have negative consequences on the disease course. Recurrent infections are most commonly caused by Staphylococcus aureus and herpes simplex virus; these can also lead to infections of other organ systems including the lungs and the urinary tract. Prevention and treatment of infections in patients with AD may require topical and systemic antimicrobials, appropriate skin care and efective control of AD signs and symptoms.
File in questo prodotto:
File Dimensione Formato  
napolitano AD infection AJCD 2025.pdf

accesso aperto

Licenza: Dominio pubblico
Dimensione 861.22 kB
Formato Adobe PDF
861.22 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1155828
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 3
social impact